Biomarkers in advance colorectal cancer patients treated with bevacizumab-containing chemotherapy

2011 Fiscal Year Final Research Report

• Project/Area Number: 21591741
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: 公益財団法人がん研究会 (2011); Japanese Foundation For Cancer Research (2009-2010)
• Principal Investigator: MATSUSAKA Satoshi 公益財団法人がん研究会, がん化学療法センター臨床部, 研究員 (00372665)
• Project Period (FY): 2009 – 2011
• Keywords: 大腸癌 / 化学療法薬 / バイオマーカー / 血管新生抑制剤 / bevacizumab / 末梢循環癌細胞(CTC) / 末梢循環血管内皮細胞(CEC) / 末梢循環血管内皮前駆細胞(CEP)

Research Abstract

This study investigated the prognosis of metastatic colorectal cancer treated with bevacizumab in combination with chemotherapy, focusing on circulating tumor cells, endothelial cells, and endothelial progenitors. We concluded the CEC status at the baseline and CEP on the day4 was correlated with the prognosis of patients treated with bevacizumab, suggesting that CEC, especially CXCR4-positive CEC, and CEP status may be useful in estimating prognosis.

Research Products

• [Journal Article] Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab (2011)
  • Author(s): Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K
  • Journal Title: Cancer Volume: 117 Pages: 4026-32
• [Journal Article] Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer (2011)
  • Author(s): Matsusaka S, Suenaga M, Mishima Y, Kuniyoshi R, Takagi K, Terui Y, Mizunuma N, Hatake K
  • Journal Title: Cancer Sci Volume: 102(6) Pages: 1188-92
• [Journal Article] Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer (2011)
  • Author(s): Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, Mizunuma N, Hatake K
  • Journal Title: Cancer Chemother Pharmacol Volume: 68(3) Pages: 763-8
• [Journal Article] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients (2011)
  • Author(s): Suenaga M, Matsusaka S, Ueno M, Yamamoto N, Shinozaki E, Mizunuma N, Yamaguchi T, Hatake K
  • Journal Title: Surgery Today Volume: 41(8) Pages: 1067-74
• [Journal Article] How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer (2011)
  • Author(s): Suenaga M, Matsusaka S, Watanabe T, Kuboki Y, Shinozaki E, Chin K, Mizunuma N, Ueno M, Yamaguchi T, Hatake K
  • Journal Title: Asia Pac J Clin Oncol Volume: 7(2) Pages: 129-35
• [Journal Article] Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer (2010)
  • Author(s): Matsusaka S, Chin K, Ogura M, Suenaga M, Shinozaki E, Mishima Y, Terui Y, Mizunuma N, Hatake K
  • Journal Title: Cancer Sci Volume: 101(4) Pages: 1067-71
• [Journal Article] Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab (2010)
  • Author(s): Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M, Fujiwara Y, Matsueda K, Konishi F, Hatake K
  • Journal Title: Med Oncol Volume: 27(3) Pages: 807-14
• [Journal Article] CROとSMO Drug Delivery (2010)
  • Author(s): 松阪諭
  • Journal Title: System Volume: 25(6) Pages: 615-616
• [Journal Article] Bevacizumabのバイオマーカー (2010)
  • Author(s): 松阪諭
  • Journal Title: 腫瘍内科 Volume: 6(3) Pages: 261-265
• [Journal Article] Chemotherapy for small-bowel Adenocarcinoma at a single institution (2009)
  • Author(s): Suenaga M, Mizunuma N, Chin K, Matsusaka S, Shinozaki E, Oya M, Ueno M, Yamaguchi T, Muto T, Konishi F, Hatake K
  • Journal Title: Surg Today Volume: 39(1) Pages: 27-31
• [Journal Article] Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan (2009)
  • Author(s): Suenaga M, Mizunuma N, Shouji D, Shinozaki E, Matsusaka S, Chin K, Oya M, Yamaguchi T, Muto T, Hatake K
  • Journal Title: J Gastroenterol Volume: 43(11) Pages: 842-8
• [Journal Article] 抗体医薬に対するバイオマーカー (2009)
  • Author(s): 松阪諭
  • Journal Title: 医学のあゆみ Volume: 228 Pages: 1105-1108
• [Journal Article] CECとベバシズマブ感受性予測 (2009)
  • Author(s): 松阪諭
  • Journal Title: 腫瘍内科 Volume: 3 Pages: 229-232
• [Journal Article] 抗VEGFモノクローナル抗体Bevacizumabとバイオマーカー (2009)
  • Author(s): 松阪諭
  • Journal Title: 大腸癌FRONTIER Volume: 2 Pages: 39-43
• [Journal Article] 大腸癌化学療法のバイオマーカー (2009)
  • Author(s): 松阪諭
  • Journal Title: 癌と化学療法 Volume: 36(1) Pages: 11-14
• [Presentation] Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer (2011)
  • Author(s): Matsusaka S, et al
  • Organizer: ASCO Gastrointestinal Cancer Symposium
  • Place of Presentation: San-Francisco
  • Year and Date: 20110000
• [Presentation] Tie2-expressing myeloid cells are predictive marker for bevacizumab-containing chemotherapy in metastatic colorectal cancer (2011)
  • Author(s): Matsusaka S, et al
  • Organizer: The European Multidisciplinary Cancer Congress
  • Place of Presentation: Stockholm
  • Year and Date: 20110000
• [Presentation] Are circulating tumor cells(CTC) and EGFR status of CTC useful as a surrogate marker for determining response to cetuximab in metastatic colorectal cancer (2010)
  • Author(s): Matsusaka S, et al
  • Organizer: ASCO Gastrointestinal Cancer Symposium
  • Place of Presentation: San-Francisco
  • Year and Date: 20100000
• [Presentation] Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumab in mCRC (2010)
  • Author(s): Matsusaka S, et al
  • Organizer: ASCO annual meeting
  • Place of Presentation: Chicago
  • Year and Date: 20100000
• [Presentation] Circulating Tumor Cells and Circulating Endothelial Cells are useful as surrogate markers for FOLFOX4 aitn or aithout bevacizumab in mCRC (2009)
  • Author(s): Matsusaka S, et al
  • Organizer: ASCO Gastrointestinal Cancer Symposium
  • Place of Presentation: San-Francisco
  • Year and Date: 20090000
• [Presentation] Circulating tumor cells(CTCs) as a surrogate marker for determining response to chemotherapy in advanced gastric cancer(AGC) (2009)
  • Author(s): Matsusaka S, et al
  • Organizer: ASCO annual meeting
  • Place of Presentation: Orlando, FL
  • Year and Date: 20090000
• [Book] CTCによるトランスレーショナルレサーチ,細胞工学別冊がん転移臨床と研究の羅針盤 (2010)
  • Author(s): 松阪諭
  • Total Pages: 176-179